Daridorexant matching placebo clinical trials

Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography, dosefinding study assessing the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder

This study is looking at a new sleep medicine, daridorexant (also known as QUVIVIQ), for young people aged 10-17 who have trouble sleeping (insomnia). It aims to find the right dose and see how well and safely it works to improve sleep.